A major UK-wide cancer study has helped establish new standards for the planning and delivery of radiotherapy for patients with locally advanced rectal cancer, benefiting patients across the UK, including those in North-east Scotland.
The ARISTOTLE trial investigated whether adding the chemotherapy drug irinotecan to the current standard treatment of radiotherapy and capecitabine (an oral chemotherapy medication) could improve outcomes for patients with high-risk rectal cancer before surgery.
The study, published in Lancet Oncology, found that adding irinotecan did not improve patients' chances of remaining free from cancer after treatment and was associated with more side effects.
As a result, researchers concluded that the drug should not be added to standard pre-operative chemoradiotherapy for this group of patients.
The study involved 75 hospitals across the UK and while the result did not show a survival benefit from the additional treatment, researchers say the trial has delivered important and lasting benefits for cancer care across the UK.
One of the study's most significant achievements was to develop a new, consistent approach to planning and delivering pelvic radiotherapy.
As part of the trial, a comprehensive quality assurance (QA) programme was also introduced to ensure treatments were delivered safely and accurately across every participating centre.
The study team also ran educational workshops throughout the UK, helping to share best practice and improve standards of care. These workshops were attended not only by experienced consultant clinicians but also by doctors and radiotherapy professionals in training, helping to embed these approaches into routine practice for future generations of cancer specialists.
Patients in North-east Scotland and across the UK have benefited from these improvements, as the standards established through the trial continue to influence how pelvic radiotherapy is planned and delivered today.
Dr Leslie Samuel, Honorary Clinical Chair in Oncology at the University of Aberdeen and a Consultant Oncologist at NHS Grampian was one of the authors of the paper.
He said: "Although the study showed that adding irinotecan did not improve survival outcomes for patients, the wider impact of ARISTOTLE has been substantial. The trial helped establish a robust national standard for pelvic radiotherapy planning and delivery, supported by a quality assurance programme and educational workshops. These improvements have benefited patients across the UK, including here in the North-east of Scotland.
"The research has also continued to deliver benefits beyond the original study. Information and samples collected through ARISTOTLE, alongside a long-standing Grampian patient database, have helped scientists develop new ways of predicting which patients are most likely to respond well to treatment. This could help doctors tailor treatment more effectively in the future and is a great example of how research carried out in the North-east contributes to advances in cancer care worldwide."
The ARISTOTLE trial represents an important example of how clinical research can improve patient care, not only through the treatments it tests, but also by raising standards, improving consistency and helping healthcare professionals deliver the best possible care.